Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
Sagimet Biosciences received FDA IND clearance and a “Study May Proceed” letter for its Phase 3 trial of denifanstat in moderate to severe acne. The pivotal trial is on track to begin in the second half of 2026 and aims to enroll approximately 800 U.S. patients, including 450 adolescents, assessing efficacy over 12 weeks and safety over a 40-week extension.
Key figures
- Drug Name
- denifanstat
- Phase Of Trial
- Phase 3
- Dosage mg
- 50
- Patients enrolled
- 800
- Adolescent patients
- 450
- Us market size annual
- 50 million
- Extension duration weeks
- 40
- Treatment duration weeks
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.